Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

Novavax's combo and standalone flu shots triggered a 2.4–5.7x rise in immune response over baseline in seniors. Over 98% of adverse events were mild or moderate in Novavax's Phase 3 trial of ...

The FDA has authorized the first over-the-counter combination COVID-19 and flu test outside of emergency use, which delivers results at home in about 15 minutes. ABC News Live ...

Novavax has submitted an application to the Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine as a booster in adults that can be used on top of its primary ...

The U.S. FDA approved 14 drugs in May, a decline from 20 in April and 22 in March. That brings the year-to-date total for 2025 to 84 approvals, the second highest on record for this period, just ...

Novavax’s deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under ...

Novavax's COVID-Flu Combo Vaccine Shows Strong ... combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi's flu shot ... Funds to Buy and Hold.

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against ...